Participated · Equity · Aug 2024

Orderly Network is a remote developer of a permissionless liquidity layer for Web3 trading led by Ran Yi. Built on omnichain infrastructure, it enables deep liquidity for any asset across multiple blockchains and avoids the risks of wrapped asset movement through cross-chain bridging. The platform empowers developers to create a comprehensive array of financial products for traders of any level. It currently supports six chains: Polygon, Arbitrum, Optimism, Base, Ethereum mainnet, and Mantle. Orderly recently raised over $5M and says it will use the funds to bolster its capabilities and continue its innovation and growth trajectory. During its seed round the company secured $20M from institutional investors including Pantera, Sequoia China, Laser Digital, Dragonfly, and Jump. Orderly Network is a permissionless, decentralized exchange protocol and modular ecosystem built on NEAR, using an on-chain order book. Its platform includes a risk engine, matching engine, and shared asset pools designed for composability so dApps can build on top. The protocol supports financial instruments such as spot trading, margin trading, perpetual swaps, lending, and borrowing. Founded in April 2022 and incubated by NEAR and WOO Network, Orderly focuses on enabling modular dApps to utilize its on-chain order-book architecture. The company plans to use recent funding to recruit across key functions, develop and enhance products, grow the Orderly ecosystem, and establish partnerships. To enhance liquidity, Orderly will launch community lending pools allowing token holders to lend assets to market makers with single-sided liquidity provision and sustainable yields.

Participated · Equity · May 2022

BitCoke Exchange is a centralized cryptocurrency exchange focused on derivatives trading. It is regarded as the world's first Quanto swap crypto exchange and offers trader‑centric features such as fair matching, fast execution, and low fees. Original products include its Quanto swap, proprietary chart, and fund management system, which have made it popular among traders, funds, and asset management firms. BitCoke has long ranked in the top 10 by volume on the CoinMarketCap derivatives marketplace. In early 2022 the exchange raised $20 million in a strategic private round to accelerate development and to design features connecting centralized exchanges (CEX) with decentralized exchanges (DEX), and to promote its native token. Company leadership said the institutional investment underscores BitCoke's growth potential and will help explore merging CEX and DEX models.

Led · Series C · Aug 2019

Protenus is a Baltimore-based healthcare compliance analytics firm that uses AI-powered analytics to detect unauthorized EMR snooping and narcotic drug diversion. The company provides compliance analytics that give privacy, pharmacy, and compliance teams full insight into how health data is being used and alerts them to inappropriate activity. Protenus says it helps thousands of hospitals reduce risk and scale compliance. The company has been recognized by Forbes, CB Insights, KLAS, Modern Healthcare, the Baltimore Business Journal, the Baltimore Sun, and Gartner. Protenus announced a $21M Series D to accelerate growth and continued product innovation. All existing investors — including Transformation Capital, Providence Ventures, F-Prime Capital, Kaiser Permanente Ventures, Arthur Ventures and Lionbird — were joined by MemorialCare and Gaingels in the round. Protenus provides a healthcare compliance analytics platform that uses artificial intelligence to audit every access to patient records for health systems. The platform proactively identifies risks across organizations, including inappropriate access to patient data and theft or misuse of controlled substances by hospital staff. It alerts privacy, security and compliance teams to inappropriate activity and gives healthcare leaders insight into how data is being used. Protenus says the solution helps partner hospitals make decisions to protect data, patients and institutions. The company was founded in 2014 by Nick Culbertson and Robert Lord and is based in Baltimore, MD. With the new funding, Protenus intends to accelerate sales. Protenus provides a comprehensive health data auditing and privacy monitoring platform that uses artificial intelligence to analyze every single action inside a medical record system. The platform is currently used by top health systems and academic medical centers across the country. The company raised $11M in a Series B to accelerate sales and customer support hiring and to invest in R&D to expand platform capabilities. Protenus was founded in 2014 by CEO Nick Culbertson and is based in Baltimore, MD. Protenus builds AI-driven software to protect patient privacy and prevent health data breaches across hospital electronic health records and associated systems. The platform leverages an array of artificial intelligence techniques to model clinical and administrative workflows and determine the appropriateness of each user action. It identifies anomalous behaviors within a hospital’s EHR and related systems to help ensure trust throughout data systems. The company said it will use the new funding to continue product development, expand product offerings and accelerate sales growth. Protenus is based in Baltimore and was founded in 2014. Senior leaders include President Robert Lord and CEO Nick Culbertson. Protenus develops a cybersecurity product described as an “immune system” for healthcare that detects violations of privacy rules such as HIPAA and prioritizes suspicious access events. The system can be deployed on-premises or in the cloud and sends targeted alerts when records are accessed. Founders Robert Lord and Nick Culbertson met at Johns Hopkins and the team includes data scientists, engineers, and designers who iterated the product through pilots and customer interviews. Early customers and pilots included Johns Hopkins and a pilot at Inova Health System; the company was part of DreamIt Health Baltimore’s 2014 accelerator class. Following a seed round and pilots, Protenus planned to scale sales and marketing and expand headcount from about 14 employees by roughly 10 more hires. The company is based in Baltimore and intends to use its Series A to accelerate growth while remaining opportunistic about hires and product implementation needs.

Led · Series B · May 2019

LetsGetChecked operates a vertically integrated, end-to-end platform that provides at-home diagnostic testing, genetic insights, virtual consultations and medication delivery. The company offers access to more than 100 laboratory panels and, following acquisitions of BioIQ, Veritas Genetics and Veritas Intercontinental, expanded services to include whole genome sequencing and pharmacogenomics. Its infrastructure includes manufacturing, logistics, state-of-the-art lab analysis, clinician support and prescription fulfillment, enabling integration with physician practices and virtual care providers via APIs. LetsGetChecked serves employers, health plans, provider groups and the public sector and has delivered more than 10 million tests and partnered with over 300 business clients across the United States, United Kingdom and EU. Founded in 2015 and co-headquartered in Dublin and New York, the company says its platform supports population-based health initiatives to address chronic conditions such as diabetes and high cholesterol. The company plans continued expansion of its 360-degree platform to scale diagnostics and virtual care access, supported by recent strategic and growth investments. LetsGetChecked provides at-home diagnostic test kits alongside telehealth and pharmacy capabilities through an end-to-end model that includes manufacturing, logistics, lab analysis, affiliated physician support, and prescription fulfillment. The company offers more than 100 validated at-home tests and has delivered over two million tests while serving more than 300 corporate customers since its 2015 founding. In the last year it says it delivered care to more than one million consumers and grew revenue by more than 1,500% year-over-year. LetsGetChecked plans to use new capital to launch "care pathways," a 360-degree remote care journey that combines telehealth, pharmacy, and diagnostics. Planned investments include expanded asynchronous chat and video telehealth, pharmacy expansion including acquiring a pharmacy in Jupiter, Florida, and continued development and rollout of new at-home tests in 2021. The company is co-headquartered in Dublin and New York and operates nationwide in the United States and in most EU countries. LetsGetChecked provides physician-approved at-home sample collection and testing with confidential results delivered online, operating a CLIA-certified high-complexity laboratory in California. Its product set includes a twin-track Coronavirus test (a rapid antibody serology result within 15 minutes followed by a PCR swab processed in its CLIA lab) and a broad catalogue of wellness, chronic condition, cancer, sexual health, fertility and pharmacogenomic tests. Users collect samples at home and return them at no additional cost via logistics partners UPS and USPS, with results available within days. The company has integrated with multiple CLIA-certified reference labs and health systems in the US and Europe and is building partnerships with insurers and employers for personalized screening and onsite employer testing. It is expanding retail distribution through 2020 and scaling supply and business operations. Following the Series C funding, LetsGetChecked intends to increase manufacturing, testing capacity and personnel to support COVID-19 testing and broader service growth across the United States and Europe. LetsGetChecked is a direct-to-consumer at-home health testing platform that enables consumers to order in-state physician-approved laboratory tests online or through retail partners. Users receive anonymized test kits shipped from the company’s ISO-accredited facility by next-day delivery, return samples for processing by CLIA-certified reference labs, and obtain results with access to in-state board-certified physicians and nurse follow-ups, including e-prescriptions at no additional cost. Its testing portfolio includes wellness, cancer screening, sexual health, fertility, genetic and pharmacogenomic tests. The platform integrates with connected health devices such as Apple Health, Fitbit and Garmin to combine lab results with wearable data for risk assessments. LetsGetChecked has integrated with large reference labs and health systems, partners with logistics providers UPS, USPS and FedEx, and is building relationships with insurers for personalized screening and home testing. The company closed a $30M Series B financing and plans to use the proceeds to scale its diagnostics consumer brand, accelerate development of its core technology platform, and expand manufacturing and logistical capabilities across North America and its served markets. LetsGetChecked is an Irish startup that offers at-home health test kits allowing customers to order, collect, and send samples for laboratory analysis across categories such as lifestyle, cancer screening, sexual health, fertility, and hormone testing. The company has built a technology and logistics platform that links customers directly to accredited laboratories, uses anonymised barcode kits, and routes results through LetsGetChecked physicians and a nursing support team who review results and call patients for positive or out-of-range findings. Users can track progress via an app dashboard and request calls from the clinical team; results are released to the dashboard after consultation when appropriate. Founded in 2014 by Peter Foley, the startup emphasizes patient-led testing and aims to mirror traditional physician-led processes while eliminating intermediaries. LetsGetChecked plans to use recent funding to scale operations, grow its full clinical support team, further invest in its technology platform and continue expanding into the U.S., where it has a New York office. Test prices vary in the U.K., ranging from £39 to £500, reflecting the company's paid consumer-facing model.